N-(2-methoxy(3-quinolyl))[(3-(4-pyridylthio)phenyl)amino]carboxamide | 473915-55-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-(2-methoxy(3-quinolyl))[(3-(4-pyridylthio)phenyl)amino]carboxamide
• 英文别名: N-(3-(2-methoxyquinolinyl))-N'-(3-(4-pyridinylthio)phenyl)urea；1-(2-Methoxyquinolin-3-yl)-3-(3-pyridin-4-ylsulfanylphenyl)urea
• CAS: 473915-55-8
• 化学式: C₂₂H₁₈N₄O₂S
• 分子量: 402.477
• InChiKey: AYEUXUJREQNJKL-UHFFFAOYSA-N

物化性质

• 沸点：
  533.5±50.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY
  申请人：Bayer Healthcare LLC

  公开号：US20160015697A1

  公开（公告）日：2016-01-21

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  这项发明涉及使用芳基脲类化合物治疗由异常血管生成或高渗透性过程特征的VEGF诱导信号转导通路介导的疾病的方法。
• Diaryl ureas with kinase inhibiting activity
  申请人：Wilhelm Scott

  公开号：US20070020704A1

  公开（公告）日：2007-01-25

  The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.

  本发明提供了使用芳基脲类化合物治疗与信号转导通路相关的疾病和病状的方法，该信号转导通路至少包括raf、VEGFR、PDGFR、p38和/或FLT-3。本发明还提供了用于鉴定可以通过本发明化合物调节的疾病和病状的组合物和方法。这些方法有助于选择可以有效治疗本发明化合物的受试者。此外，本发明还提供了监测已经接受本发明化合物治疗的受试者的方法。
• Aryl Ureas With Angiogenisis Inhibiting Activity
  申请人：Dumas Jacques

  公开号：US20080227828A1

  公开（公告）日：2008-09-18

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的异常血管生成或高渗透过程引起的疾病的方法。
• DIARYL UREAS AND COMBINATIONS
  申请人：Wilhelm Scott

  公开号：US20090068146A1

  公开（公告）日：2009-03-12

  The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I): B—NH—C(O)—NH-L-M-L 1 -(Q) 1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. each Q is independently C(O)R 4 , C(O)OR 4 and C(O)NR 4 R 5 ; and L′ is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.

  本发明提供了一种治疗人类和其他哺乳动物癌症的方法，包括给予化疗药物，如干扰素，和式（I）的芳基脲化合物：B—NH—C（O）—NH-L-M-L1-（Q）1-3（I）。在式（I）中，B和L各自独立地是可选取代的苯基，萘基，5或6个成员的单环杂芳基团，或8到10个成员的双环杂芳基团；M是桥接基；每个Q独立地是C（O）R4，C（O）OR4和C（O）NR4R5；L'是可选取代的苯基，萘基，单环杂芳基或双环杂芳基，或饱和或部分饱和的单环或双环碳环或杂环基团。
• ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：DUMAS Jacques

  公开号：US20120289552A1

  公开（公告）日：2012-11-15

  This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

  本发明涉及使用芳基脲类化合物治疗由VEGF诱导的信号转导通路介导的以异常血管生成或高渗透过程为特征的疾病的方法。